LEXINGTON, Mass. --(BUSINESS WIRE)--Apr. 26, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2018 financial results on Thursday, May 3, 2018 , before the U.S. financial markets open. The Company will host a conference call and webcast at
Topline Phase 2a Data from the 4 mg and 8 mg Cohorts Expected in Fourth Quarter of 2018 LEXINGTON, Mass. --(BUSINESS WIRE)--Apr. 25, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of its Phase 2a trial evaluating CTP-543 for the
LEXINGTON, Mass. --(BUSINESS WIRE)--Mar. 6, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The Cowen 38th Annual Healthcare Conference on March 13, 2018 at 11:20 a.m.
CTP-543 On Track to Report Topline Phase 2a Results in Alopecia Areata by Year-End New Neuropsychiatric Product Candidate Poised to Enter Clinical Development in 2018 Conference Call Scheduled Today at 8:30 a.m. ET LEXINGTON, Mass. --(BUSINESS WIRE)--Mar. 1, 2018-- Concert Pharmaceuticals, Inc.
CTP-692 Poised to Enter Clinical Development in 2018 as an Adjunctive Treatment of Schizophrenia Conference Call Scheduled Tomorrow at 8:30 a.m. ET for Company Update and 2017 Financial Results LEXINGTON, Mass. --(BUSINESS WIRE)--Feb. 28, 2018-- Concert Pharmaceuticals, Inc.
LEXINGTON, Mass. --(BUSINESS WIRE)--Feb. 21, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the year ended December 31, 2017 , on Thursday, March 1, 2018 , before the U.S. financial markets open.
Phase 2a Trial On Track to Complete in Second Half of 2018 LEXINGTON, Mass. --(BUSINESS WIRE)--Feb. 12, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated enrollment of the second cohort of its Phase 2a clinical trial evaluating CTP-543.
CTP-543 is a Novel JAK Inhibitor in Phase 2 for Alopecia Areata as Potential First-in-Class Treatment LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CTP-543, a
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has decided not to grant the Company's Post Grant Review (PGR) petition challenging the validity of U.S. Patent No.
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the appointment of Marc Becker as Chief Financial Officer, effective January 4, 2018 . Mr. Becker is a seasoned financial executive with more than 15 years of experience in the biotechnology industry.
